nirsevimab-alip (Beyfortus)

Indications

• treatment of respiratory syncytial virus (RSV
  • neonates & infants born during or entering their 1st RSV season
  • children <= 24 months of age vulnerable to severe RSV disease through their 2nd RSV season

Dosage

• neonates & infants born during or entering their 1st RSV season
  • 50 mg IM if < 5 kg
  • 100 mg IM if >= 5 kg
• children <= 24 months of age vulnerable through their 2nd RSV season
  • 2 doses 100 mg IM

Injection: 100 mg/mL in a single-dose pre-filled syringe

Mechanism of action

• IgG1 monoclonal antibody, RSV F protein-directed fusion inhibitor

More general terms

• antiviral agent
• pharmaceutical monoclonal antibody